Masimo is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors.

 
 
  • Oxygen Reserve Index (ORi™)
  • A noninvasive and continuous parameter that provides insight into a patient’s oxygen reserve
 
  • rainbow® Pulse CO-Oximetry
  • The Masimo rainbow SET™ platform has the unique ability to measure dyshemoglobins and total hemoglobin concentration.
 
 
  • CCHD Screening
  • Reliable, Accurate Screening for Critical Congenital Heart Disease (CCHD) with Masimo SET®

News & Media

 
  • May 14, 2018
  • Madrid, Spain
  • Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers evaluated the utility of Masimo noninvasive and continuous hemoglobin (SpHb®) in reducing the number of unnecessary blood transfusions, thus reducin […]
  • May 7, 2018
  • Salt Lake City, Utah
  • The Utah State Legislature and Governor Gary Herbert have recently signed into law the Concurrent Resolution on Deaths From Opioid-Induced Postoperative Respiratory Depression (SCR4). The resolution urges hospitals, clinicians, and researchers to exa […]
  • May 2, 2018
  • Irvine, California
  • Masimo (NASDAQ: MASI) today announced its financial results for the first quarter ended March 31, 2018. First Quarter 2018 Results: First quarter 2018 total revenue, inc […]
  • October 2, 2008
  • Masimo SET $1 Million Performance Guarantee
  • In keeping with Masimo’s mission to improve patient care, and to help clinicians separate fact from fiction, Masimo is renewing and expanding its performance guarantee. […]
  • February 23, 2018
  • Patient Safety Movement
  • The Patient Safety Movement Foundation believes reaching ZERO preventable deaths in hospitals by 2020 (0X2020™) is not only the right goal, but an attainable one with the […]
  • May 1, 2017
  • 2016 Masimo Annual Report
  • 2016 Masimo Annual Report - Through Movement. The first phase of our 10-year plan was to invest in R&D and key functional areas, allowing the company to gain a worldwide […]

Next Generation SedLine is not licensed for sale in Canada.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.

Improve Patient Outcomes and Reduce the Cost of Care.

© 2018 Masimo. All Rights Reserved.